	US 12,324,818 B2
	Generation of alveolar epithelial type 1 (AT1) cells
Claire Burgess, Boston, MA (US); and Darrell Kotton, Newton, MA (US)
Assigned to TRUSTEES OF BOSTON UNIVERSITY
Filed by TRUSTEES OF BOSTON UNIVERSITY, Boston, MA (US)
Filed on Dec. 15, 2023, as Appl. No. 18/541,448.
Claims priority of provisional application 63/434,299, filed on Dec. 21, 2022.
Prior Publication US 2024/0261337 A1, Aug. 8, 2024
Int. Cl. A61K 35/42 (2015.01); C12N 5/071 (2010.01); C12N 15/86 (2006.01)

CPC A61K 35/42 (2013.01) [C12N 5/0688 (2013.01); C12N 15/86 (2013.01); C12N 2500/90 (2013.01); C12N 2501/11 (2013.01); C12N 2501/117 (2013.01); C12N 2501/119 (2013.01); C12N 2501/727 (2013.01); C12N 2513/00 (2013.01); C12N 2740/15043 (2013.01)]

13 Claims

1. A method comprising culturing at least one alveolar epithelial cell type II (AT2) cell and/or lung epithelial progenitor cell in a medium comprising a Large Tumor Suppressor Kinase (LATS) inhibitor;

wherein said culturing results in the differentiation of the at least one AT2 cell and/or lung epithelial progenitor cell to an alveolar epithelial cell type I (AT1) cell.